{"DataElement":{"publicId":"2904614","version":"1","preferredName":"Sunitinib Administered Medication Route of Administration Type","preferredDefinition":"A description of the route of administration for the administered sunitinib.","longName":"2867304v1.0:2486452v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2867304","version":"1","preferredName":"Sunitinib Administered","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells._The act of having given something (e.g., a medication or test).","longName":"2867302v1.0:2233610v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2867302","version":"1","preferredName":"Sunitinib","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","longName":"C71622","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"692F8C4C-BAE2-B5A9-E040-BB89AD43033E","latestVersionIndicator":"Yes","beginDate":"2009-05-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-05-05","modifiedBy":"ONEDATA","dateModified":"2009-05-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2233610","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F95D94B9-D864-2792-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-13","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-06-13","modifiedBy":"ONEDATA","dateModified":"2005-06-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"692F8C4C-BAF0-B5A9-E040-BB89AD43033E","latestVersionIndicator":"Yes","beginDate":"2009-05-05","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-05-05","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2486452","version":"1.1","preferredName":"Medication Route of Administration Type","preferredDefinition":"A drug or medicine that treats or prevents or alleviates the symptoms of disease._The course by which a substance was administered in order to reach the site of action in the body._Type; a subdivision of a particular kind of thing.","longName":"2486452v1.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"IV","valueDescription":"Intravenous Route of Administration","ValueMeaning":{"publicId":"2578035","version":"1","preferredName":"Intravenous Route of Administration","longName":"2578035","preferredDefinition":"Administration within or into a vein or veins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDE0-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF40627-BBF0-1B28-E040-BB89AD435609","beginDate":"2006-06-09","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","deletedIndicator":"No"},{"value":"Oral","valueDescription":"Oral Route of Administration","ValueMeaning":{"publicId":"2581009","version":"1","preferredName":"Oral Route of Administration","longName":"2581009","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-097E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"SBREXT","dateModified":"2007-06-25","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF40627-BBFA-1B28-E040-BB89AD435609","beginDate":"2006-06-09","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","deletedIndicator":"No"},{"value":"IP","valueDescription":"Intraperitoneal Route of Administration","ValueMeaning":{"publicId":"2578020","version":"1","preferredName":"Intraperitoneal Route of Administration","longName":"2578020","preferredDefinition":"Administration within the peritoneal cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intraperitoneal Route of Administration","conceptCode":"C38258","definition":"Administration of a drug via injection or infusion of a substance into the peritoneum, where it is absorbed by the lining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FDD1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-28","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-28","modifiedBy":"ONEDATA","dateModified":"2006-02-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF40627-BC49-1B28-E040-BB89AD435609","beginDate":"2009-06-22","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","deletedIndicator":"No"},{"value":"Oral and IV","valueDescription":"Oral Route of Administration Intravenous Route of Administration","ValueMeaning":{"publicId":"2740967","version":"1","preferredName":"Oral Route of Administration Intravenous Route of Administration","longName":"2740967","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: Administration within or into a vein or veins.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4AEA449B-832A-45AE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ALEYR","dateCreated":"2008-04-15","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF40627-BC5D-1B28-E040-BB89AD435609","beginDate":"2006-06-09","endDate":"2013-09-09","createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"KUMMEROA","dateModified":"2013-09-09","deletedIndicator":"No"},{"value":"Not Given","valueDescription":"Negation Administration","ValueMeaning":{"publicId":"2866822","version":"1","preferredName":"Negation Administration","longName":"2866822","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: The act of administration.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administration","conceptCode":"C25409","definition":"The act of the dispensing, applying, or tendering of something to another, such as administration of a medicine.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68CBB2B0-BAB9-039B-E040-BB89AD43439D","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF40627-BD2B-1B28-E040-BB89AD435609","beginDate":"2009-06-22","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","deletedIndicator":"No"},{"value":"IV & IP","valueDescription":"Intravenous Route of Administration And Intraperitoneal Route of Administration","ValueMeaning":{"publicId":"2866823","version":"1","preferredName":"Intravenous Route of Administration And Intraperitoneal Route of Administration","longName":"2866823","preferredDefinition":"Administration within or into a vein or veins.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Administration within the peritoneal cavity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Intraperitoneal Route of Administration","conceptCode":"C38258","definition":"Administration of a drug via injection or infusion of a substance into the peritoneum, where it is absorbed by the lining.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"68CBB2B0-BAFE-039B-E040-BB89AD43439D","latestVersionIndicator":"Yes","beginDate":"2009-04-30","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-04-30","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF40627-BD35-1B28-E040-BB89AD435609","beginDate":"2009-06-22","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","deletedIndicator":"No"},{"value":"Route Unknown","valueDescription":"Unknown Route of Administration","ValueMeaning":{"publicId":"2577944","version":"1","preferredName":"Unknown Route of Administration","longName":"2577944v1.00","preferredDefinition":"The route of drug administration is unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown Route of Administration","conceptCode":"C38311","definition":"The route of drug administration is unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD85-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-26","endDate":null,"createdBy":"FRAZIERP","dateCreated":"2006-02-26","modifiedBy":"CLOHNES","dateModified":"2023-07-11","changeDescription":null,"administrativeNotes":"7/11/23 Edited so definition of VM is visible per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6CF5DE01-B216-5ED7-E040-BB89AD430877","beginDate":"2009-06-22","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"ONEDATA","dateModified":"2009-06-22","deletedIndicator":"No"},{"value":"Both","valueDescription":"Oral Route of Administration And Intravenous Route of Administration Both","ValueMeaning":{"publicId":"3883032","version":"1","preferredName":"Oral Route of Administration And Intravenous Route of Administration Both","longName":"3883032","preferredDefinition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.: An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.: Administration within or into a vein or veins.: One and the other; relating to or being two in conjunction.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Oral Route of Administration","conceptCode":"C38288","definition":"The introduction of a substance to the mouth or into the gastrointestinal tract by the way of the mouth, usually for systemic action. It is the most common, convenient, and usually the safest and least expensive route of drug administration, but it uses the most complicated pathway to the tissues and bioavailability varies. The disadvantages of method are hepatic first pass metabolism and enzymatic degradation of the drug within the gastrointestinal tract. This prohibits oral administration of certain classes of drugs especially peptides and proteins.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"And","conceptCode":"C37912","definition":"An article which expresses the relation of connection or addition. It is used to conjoin a word with a word, a clause with a clause, or a sentence with a sentence.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Intravenous Route of Administration","conceptCode":"C38276","definition":"Administration of a drug within or into a vein or veins. Introduction of the drug directly into venous circulation results in 100% bioavailability due to an absence of the absorption phase, provides a precise and continuous mode of drug therapy, especially for drugs with a narrow therapeutic index.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Both","conceptCode":"C49636","definition":"One and the other; relating to or being two in conjunction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E5F3BD56-2DA1-45A0-E040-BB89AD434122","latestVersionIndicator":"Yes","beginDate":"2013-09-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-09-09","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E5F3BD56-2DBA-45A0-E040-BB89AD434122","beginDate":"2013-09-09","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2013-09-09","modifiedBy":"ONEDATA","dateModified":"2013-09-09","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2760407","version":"1","preferredName":"Medication Route of Administration Type","preferredDefinition":"biologically active substance, including those intended for use in diagnosis, treatment, or prevention of disease or other abnormalities, for the relief of suffering, or control or improvement of a physical or mental state; includes biological products.:The course by which a substance was administered in order to reach the site of action in the body.:Type; a subdivision of a particular kind of thing.","longName":"C459:C38114:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Medication","conceptCode":"C459","definition":"A drug product that contains one or more active and/or inactive ingredients; it is intended to treat, prevent or alleviate the symptoms of disease. This term does not refer to the individual ingredients that make up the product.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Route of Administration","conceptCode":"C38114","definition":"Designation of the part of the body through which or into which, or the way in which, the medicinal product is intended to be introduced. In some cases a medicinal product can be intended for more than one route and/or method of administration.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5007EC41-4612-6ABB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-06-19","endDate":null,"createdBy":"NYCHM","dateCreated":"2008-06-19","modifiedBy":"ONEDATA","dateModified":"2008-06-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6CF40627-BBCF-1B28-E040-BB89AD435609","latestVersionIndicator":"Yes","beginDate":"2006-06-09","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-22","modifiedBy":"KUMMEROA","dateModified":"2013-09-09","changeDescription":". Added PV \"Both\" AK 9/9/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2842912","version":"1","longName":"Therapy","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2842916","version":"1","longName":"Systemic","context":"NHLBI"}]}],"AlternateNames":[{"name":"oc_base_tx_sunitini_yn","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the route of adminis","type":"Preferred Question Text","description":"What was the route of administration for sunitinib?","url":null,"context":"NHLBI"},{"name":"sunitinib (Sutent, SU11248)","type":"Alternate Question Text","description":"sunitinib (Sutent, SU11248)","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"6D09972A-5F0E-7C2C-E040-BB89AD43336B","latestVersionIndicator":"Yes","beginDate":"2009-06-23","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-06-23","modifiedBy":"KUMMEROA","dateModified":"2021-05-13","changeDescription":". 2021-5-13 ak OK to release per WZ. 2021-3-31 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}